Salticin may be available in the countries listed below.
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Salticin in the following countries:
International Drug Name Search
Aludex may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amitraz is reported as an ingredient of Aludex in the following countries:
International Drug Name Search
In the US, Micardis HCT (hydrochlorothiazide/telmisartan systemic) is a member of the drug class antihypertensive combinations and is used to treat High Blood Pressure.
US matches:
Hydrochlorothiazide is reported as an ingredient of Micardis HCT in the following countries:
Telmisartan is reported as an ingredient of Micardis HCT in the following countries:
International Drug Name Search
Buflomed may be available in the countries listed below.
Buflomedil is reported as an ingredient of Buflomed in the following countries:
Buflomedil hydrochloride (a derivative of Buflomedil) is reported as an ingredient of Buflomed in the following countries:
International Drug Name Search
Class: Genitourinary Smooth Muscle Relaxants
Chemical Name: (S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide
Molecular Formula: C28H30N2O2
CAS Number: 133099-04-4
Brands: Enablex
Genitourinary antispasmodic agent; an antimuscarinic agent.1
Relief of symptoms associated with voiding (e.g., urge urinary incontinence, urgency, frequency).1
Extended-release darifenacin (15 mg once daily) may be as effective as immediate-release oxybutynin (5 mg 3 times daily).5
Administer orally once daily with liquids without regard to meals.1
Swallow tablets whole; do not chew, divide, or crush.1
Available as darifenacin hydrobromide; dosage expressed in terms of darifenacin.1
Initially, 7.5 mg once daily.1 May increase after 2 weeks to 15 mg once daily according to response.1
Maximum 15 mg daily.1
No dosage adjustment required in patients with mild hepatic impairment (Child-Pugh class A).1
Maximum 7.5 mg daily in patients with moderate hepatic impairment (Child-Pugh class B).1
Use not recommended in patients with severe hepatic impairment (Child-Pugh class C).1 (See Distribution: Special Populations, under Pharmacokinetics.)
No dosage adjustment required.1 8
No dosage adjustment required.1
Urinary retention, gastric retention, or uncontrolled angle-closure glaucoma or risk of these conditions.1
Known hypersensitivity to darifenacin or any ingredient in the formulation.1
Severe acute urinary retention requiring treatment reported in some patients receiving higher than recommended dosages (e.g., 30 mg daily) and in patients with detrusor hyperreflexia secondary to a stroke, benign prostatic hypertrophy, or irritable bowel syndrome.1 Acute urinary retention requiring bladder catheterization for 1–2 days also reported at therapeutic dosages.1
Use with caution in patients with clinically important bladder outflow obstruction.1
May decrease GI motility; use with caution in patients with severe constipation, ulcerative colitis, or myasthenia gravis.1 Severe constipation reported.1
Risk of gastric retention; use with caution in patients with obstructive GI disorders.1
In patients being treated for angle-closure glaucoma, use only if potential benefits outweigh risks.1 (See Contraindications under Cautions.)
Category C.1
Distributed into milk in rats; not known whether distributed into human milk.1 Use caution.1
Safety and efficacy not established in pediatric patients.1
No substantial differences in safety and efficacy relative to younger adults.1 (See Geriatric Patients under Dosage and Administration and see Elimination: Special Populations, under Pharmacokinetics.)
Use not evaluated and not recommended in patients with severe hepatic impairment (Child-Pugh class C).1 (See Hepatic Impairment under Dosage and Administration and see Distribution: Special Populations, under Pharmacokinetics.)
Dry mouth, constipation.1
Metabolized principally by CYP2D6 and CYP3A4.1 May inhibit CYP2D6 and CYP3A4; not expected to inhibit CYP1A2 and CYP2C9.1
Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased plasma darifenacin concentrations).1 7 Do not exceed 7.5 mg daily when used concomitantly with potent inhibitors of CYP3A4.1 No dosage adjustment required when used concomitantly with moderate CYP3A4 inhibitors.1 (See Specific Drugs under Interactions.)
Inhibitors of CYP2D6: Potential pharmacokinetic interaction (increased plasma darifenacin concentrations).1 However, no dosage adjustment required.1
Mixed inhibitors of CYP isoenzymes: Potential pharmacokinetic interaction (increased plasma darifenacin concentrations).1 However, no dosage adjustment required.8
Inducers of CYP3A4: Potential pharmacokinetic interaction1 (altered plasma darifenacin concentrations).1 8
Substrates of CYP3A4: Potential pharmacokinetic interaction (increased plasma substrate concentrations).1
Substrates of CYP2D6: Potential pharmacokinetic interaction (increased plasma substrate concentrations).1 Caution advised when used concomitantly with CYP2D6 substrates that have a narrow therapeutic index.1
Substrates of CYP1A2 or CYP2C9: Pharmacokinetic interaction not expected at therapeutic dosages.8
Potential pharmacokinetic interaction (altered absorption because of decreased GI motility).1 (See Decreased GI Motility under Cautions.)
Drug | Interaction | Comments |
|---|---|---|
Anticholinergic agents | Possible additive anticholinergic effects (e.g., decreased GI motility; altered absorption of other drugs)1 | |
Antidepressants, tricyclics | Possible increased concentrations of tricyclic antidepressant1 | Use concomitantly with caution1 |
Cimetidine | Increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Clarithromycin | Possible increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Digoxin | Increased digoxin exposure1 | Continue routine monitoring of digoxin therapy1 |
Diltiazem | Possible increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Erythromycin | Increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Flecainide | Possible increased flecainide concentrations1 | Use concomitantly with caution1 |
Fluconazole | Increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Hormonal contraceptives | Pharmacokinetic interaction unlikely with oral contraceptives containing ethinyl estradiol and levonorgestrel1 | |
Imipramine | Increased plasma concentrations of imipramine and desipramine1 | |
Itraconazole | Possible increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Ketoconazole | Increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Midazolam | Increased midazolam concentrations1 | |
Nefazodone | Possible increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Nelfinavir | Possible increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Paroxetine | Increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Ritonavir | Possible increased plasma darifenacin concentrations1 | Do not exceed a darifenacin dosage of 7.5 mg daily1 |
Thioridazine | Possible increased thioridazine concentrations1 | Use concomitantly with caution1 |
Verapamil | Possible increased plasma darifenacin concentrations1 | No dosage adjustment required1 |
Warfarin | No substantial effect on PT1 | Continue routine monitoring of PT1 |
Mean oral bioavailability at steady-state is approximately 15 or 19% for the 7.5- or 15-mg tablets, respectively.1 7
Peak plasma concentrations achieved approximately 7 hours after multiple dosing.1
Symptomatic improvement (i.e., reduction in number of urge incontinence episodes) observed within first 2 weeks of therapy.1 6
Food does not affect darifenacin pharmacokinetics.1
Darifenacin exposure is 40 or 90% higher in CYP2D6 heterozygote-extensive metabolizers or poor metabolizers, respectively, and 56% lower in Japanese males.7
Distributed into milk in rats; not known whether distributed into human milk.1
Approximately 98% (mainly to α1-acid glycoprotein).1
In patients with moderate hepatic impairment (Child-Pugh class B), decreased protein binding resulting in increased darifenacin exposure observed.1 (See Hepatic Impairment under Dosage and Administration.)
Extensively metabolized in the liver, mainly via CYP2D6 and CYP3A4.1
Excreted in urine (60%) and in feces (40%); unchanged drug accounts for about 3% of recovered radioactivity.1
Approximately 13–19 hours following long-term administration.1
In patients with poor metabolizer CYP2D6 phenotypes (approximately 7% of Caucasians and 2% of African Americans), darifenacin is metabolized principally via CYP3A4; decreased clearance observed.1 7 Steady-state plasma concentrations following 15-mg daily dosage approximately 1.7–1.9 times higher in poor metabolizers than in extensive metabolizers.1
In geriatric patients, possible decreased clearance (decreases about 6% per decade beginning at 44 years of age).1
In patients with renal impairment, no clear relationship between extent of impairment and darifenacin clearance observed in patients with Clcr 10–136 mL/minute.1 (See Renal Impairment under Dosage and Administration.)
25°C (may be exposed to 15–30°C).1 Protect from light.1
Potent and selective antimuscarinic agent.1
Inhibits binding of acetylcholine to muscarinic receptors in cholinergically innervated organs.8
Demonstrates substantially greater binding affinity for muscarinic M3 receptors (which are involved in contraction of detrusor muscle of bladder and GI smooth muscle, saliva production, and iris sphincter function) in vitro than for other muscarinic receptor subtypes.1 3 8 Exhibits functional selectivity for urinary bladder over secretory (e.g., salivary) glands.2 3
Increases bladder capacity and diminishes frequency of unstable contractions of detrusor muscle in patients with involuntary detrusor contractions.1
Risk of constipation, urinary retention, blurred vision, and heat prostration (when used in a hot environment).1 4 Use caution when driving or performing dangerous activities until effects on vision are known.4
Importance of taking tablets with liquids and swallowing whole; do not chew, divide, or crush.1 4 If a dose is skipped, resume therapy the next day; do not take 2 doses in the same day.4
Importance of reading manufacturer’s patient information leaflet before initiating therapy.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.1
Importance of advising patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, extended-release | 7.5 mg (of darifenacin) | Enablex | Novartis |
15 mg (of darifenacin) | Enablex | Novartis |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Enablex 15MG 24-hr Tablets (WARNER CHILCOTT PROF PROD DIV): 30/$152.38 or 90/$435.37
Enablex 7.5MG 24-hr Tablets (WARNER CHILCOTT PROF PROD DIV): 30/$146.34 or 90/$420.87
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions June 2005. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Novartis. Enablex (darifenacin hydrobromide) extended-release tablets prescribing information. East Hanover, NJ; 2004 Dec.
2. Miyamae K, Yoshida M, Murakami S et al. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology. 2003; 69:205-11. [PubMed 14624061]
3. Croom KF, Keating GM. Darifenacin in the treatment of overactive bladder. Drugs Aging. 2004; 21:885-92. [PubMed 15493952]
4. Novartis. Enablex (darifenacin hydrobromide) extended-release tablets patient information. East Hanover, NJ; 2004 Dec.
5. Zinner N, Tuttle J, and Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder. Joint Meeting of the International Continence Society and the International Urogynecological Association. Paris: 2004. Abstract No. 378. From The International Continence Society website ()
6. Haab F, Stewart L, and Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004; 45:420-9. [PubMed 15041104]
7. Kerbusch T, Wahlby U, Milligan PA et al. Population pharmacokinetic modeling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003; 56:639-52. [IDIS 508556] [PubMed 14616424]
8. Novartis, East Hanover, NJ: Personal communication.
9. Steers W, Corcos J, Foote J et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005; 95:580-6. [PubMed 15705084]
Treating inflammation (swelling, warmth, redness, pain) of the eyes and eyelids when infection or risk of infection is present.
Blephamide S.O.P. Ointment is an antibacterial and corticosteroid combination. It works by reducing the itching, redness, and swelling of the eye. It also works to stop the growth of certain bacteria that cause eye infections.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Blephamide S.O.P. Ointment. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Blephamide S.O.P. Ointment. Tell your health care provider if you are taking any other medicine, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Blephamide S.O.P. Ointment may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Blephamide S.O.P. Ointment as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Blephamide S.O.P. Ointment.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Temporary burning or stinging.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; eye pain, itching, redness, swelling, irritation, or sores not present when you began using Blephamide S.O.P. Ointment; fever, chills, or sore throat; red, swollen, or blistered skin; severe or persistent blurred vision; unusual tiredness or weakness; yellowing of the eyes or skin.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Blephamide S.O.P. side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Blephamide S.O.P. Ointment at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Do not freeze. Store away from heat and light. Keep Blephamide S.O.P. Ointment out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Blephamide S.O.P. Ointment. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: estradiol (Transdermal route)
es-tra-DYE-ol
Estrogens increase the risk of endometrial cancer; monitor for abnormal vaginal bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible .
Estrogens increase the risk of endometrial cancer; monitor for abnormal vaginal bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible.
Estrogens increase the risk of endometrial cancer; monitor for abnormal vaginal bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) have been reported. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible .
Unopposed estrogens increase the risk of endometrial cancer. Adding a progestin will reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of stroke and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogen alone have been reported. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogens combined with progestins have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported in women receiving estrogen alone or estrogen combined with progestins. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible. Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional secondary exposure. Patients should strictly adhere to recommended instructions for use .
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Endocrine-Metabolic Agent
Pharmacologic Class: Estrogen
Estradiol transdermal spray is used to treat moderate to severe hot flashes and other symptoms of menopause or low amounts of estrogen.
Estradiol is an estrogen hormone. The hormone from the spray is absorbed through your skin into your body. It works by preventing symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and sweating ("hot flashes") in women during menopause.
This medicine is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Use of estradiol transdermal spray is not indicated in the pediatric population. Safety and efficacy have not been established.
Although appropriate studies on the relationship of age to the effects of estradiol transdermal spray have not been performed in the geriatric population, no geriatric-specific problems have been documented to date. However, elderly patients are more likely to have breast cancer, stroke, or dementia, which may require caution in patients receiving estradiol transdermal spray.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | X | Studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. This drug should not be used in women who are or may become pregnant because the risk clearly outweighs any possible benefit. |
Studies suggest that this medication may alter milk production or composition. If an alternative to this medication is not prescribed, you should monitor the infant for side effects and adequate milk intake.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
This section provides information on the proper use of a number of products that contain estradiol. It may not be specific to Divigel. Please read with care.
It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects.
This medicine is for use on the skin only. Do not get it in your eyes, nose, mouth, breast, or vagina. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.
This medicine comes with a patient information insert. Read and follow the instructions in the insert carefully. Ask your doctor if you have any questions.
Wash your hands with soap and water before and after using this medicine.
To use the spray:
The spray contains alcohol and is flammable. Avoid using it near an open flame or while smoking.
The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Do not use Evamist® spray if it has been more than 12 hours since you missed your last dose.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly and does not cause unwanted effects. Pelvic exam, breast exam, and mammogram (breast x-ray) may be needed to check for unwanted effects, unless your doctor tells you otherwise.
It is unlikely that a postmenopausal woman may become pregnant. But, you should know that using this medicine while you are pregnant could harm your unborn baby. If you think you have become pregnant while using the medicine, tell your doctor right away.
Using large doses of this medicine over a long period of time may increase your risk of heart attack, stroke, blood clots, dementia, breast cancer, or uterine cancer. Talk with your doctor about this risk. If you still have your uterus (womb), ask your doctor if you should also use a progestin medicine.
Your risk of heart disease or stroke from this medicine is higher if you smoke. Your risk is also increased if you have diabetes or high cholesterol, or if you are overweight. Talk with your doctor about ways to stop smoking. Keep your diabetes under control. Ask your doctor about diet and exercise to control your weight and blood cholesterol level.
Tell the medical doctor or dentist in charge that you are using this medicine before any kind of surgery (including dental surgery) or emergency treatment. Your doctor will decide whether you should continue using this medicine.
This medicine may also increase your risk of certain types of cancer. Talk to your doctor if you have concerns about this risk.
Using this medicine alone may increase your risk of getting cancer of the uterus (womb). Check with your doctor right away if you have unusual vaginal bleeding while you are using this medicine.
Stop using this medicine and check with your doctor immediately if severe headache or sudden loss of vision or any other change in vision occurs while you are using this medicine. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor).
Check with your child's doctor right away if your child starts to have the following symptoms: nipple or breast swelling or tenderness in females, or enlargement of the breasts in males. Your child may have been exposed to this medicine.
Do not allow your pets to lick or touch the arm where this medicine was applied. Small pets may be sensitive to this medicine. Call your pet's veterinarian if your pet starts to have the following symptoms: nipple or breast enlargement, swelling of the vulva, or any signs of illness.
Before you have any medical tests, tell the medical doctor in charge that you are taking this medicine. The results of some tests may be affected by this medicine.
Do not take other medicines or drink grapefruit juice unless you discuss it with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (e.g., St. John's wort) or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
